Shepherd Street Advisors LLC Makes New $1.21 Million Investment in argenex SE $ARGX

Shepherd Street Advisors LLC bought a new position in shares of argenex SE (NASDAQ:ARGX) during the 4th quarter, according to its most recent filing with the SEC. The institutional investor bought 1,442 shares of the company’s stock, valued at approximately $1,213,000. argenex makes up 1.2% of Shepherd Street Advisors LLC’s portfolio, making the stock its 28th largest position.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Abound Wealth Management grew its holdings in argenex by 3,200.0% during the 4th quarter. Abound Wealth Management now owns 33 shares of the company’s stock worth $28,000 after acquiring an additional 32 shares in the last quarter. Sound Income Strategies LLC bought a new position in argenex during the 4th quarter worth about $28,000. Ameriflex Group Inc. bought a new position in argenex during the 3rd quarter worth about $32,000. Aventura Private Wealth LLC bought a new position in argenex during the 4th quarter worth about $38,000. Finally, Sunbelt Securities Inc. bought a new position in argenex during the 3rd quarter worth about $36,000. 60.32% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of analysts have recently weighed in on the stock. Wall Street Zen cut shares of argenex from a “buy” rating to a “hold” rating in a report on Sunday, March 8th. Royal Bank Of Canada lowered their price target on shares of argenex from $925.00 to $890.00 and set an “outperform” rating on the stock in a report on Friday, February 27th. Zacks Research upgraded shares of argenex from a “strong sell” rating to a “hold” rating in a report on Friday, February 20th. HC Wainwright raised their price target on shares of argenex from $915.00 to $940.00 and gave the company a “buy” rating in a report on Friday, February 27th. Finally, Weiss Ratings restated a “hold (c)” rating on shares of argenex in a report on Monday, April 20th. Two investment analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and four have issued a Hold rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $1,019.50.

argenex Stock Performance

NASDAQ:ARGX opened at $802.17 on Wednesday. argenex SE has a fifty-two week low of $510.05 and a fifty-two week high of $934.62. The stock has a market capitalization of $49.89 billion, a P/E ratio of 35.72, a P/E/G ratio of 1.32 and a beta of 0.47. The company’s 50-day simple moving average is $782.33 and its 200-day simple moving average is $814.51.

argenex (NASDAQ:ARGX) last released its earnings results on Tuesday, March 31st. The company reported $5.52 EPS for the quarter. The company had revenue of $1.31 billion during the quarter. argenex had a net margin of 31.31% and a return on equity of 33.28%. On average, research analysts forecast that argenex SE will post 25.34 EPS for the current year.

argenex Profile

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.